Oncothyreon, a biotechnology company specialising in the development of therapeutic products for the treatment of cancer, has appointed Julie Eastland as chief financial officer (CFO) and vice president, corporate development. Eastland’s responsibilities will include financial management, investor relations and business development.
Eastland served as CFO and vice president finance and operations of VLST Corporation, a biotechnology company, from February 2006 to 2010. From 2000 to 2005, Eastland held various finance positions at Dendreon Corporation, a biotechnology company, most recently as the vice president of strategic planning.
Prior to Dendreon, Eastland worked for Amgen as area finance manager and assistant controller for its Colorado operations. She has also worked as director of finance and planning for Encore Media Group, international finance and business manager and senior financial analyst for SCIENCE Magazine, and financial manager for the Discovery Channel. Eastland received an MBA from Edinburgh University Management School and a BS in finance from Colorado State University.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.